CS414591A3 - Cytokinin synthesis inhibition factor, antagonists thereof and its use - Google Patents

Cytokinin synthesis inhibition factor, antagonists thereof and its use

Info

Publication number
CS414591A3
CS414591A3 CS914145A CS414591A CS414591A3 CS 414591 A3 CS414591 A3 CS 414591A3 CS 914145 A CS914145 A CS 914145A CS 414591 A CS414591 A CS 414591A CS 414591 A3 CS414591 A3 CS 414591A3
Authority
CS
Czechoslovakia
Prior art keywords
antagonists
inhibition factor
synthesis inhibition
cytokinin synthesis
cytokine
Prior art date
Application number
CS914145A
Other languages
Czech (cs)
English (en)
Inventor
Timothy R Mosmann
Keving W Moore
Martha W Bond
Paulo J M Vieira
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CS414591A3 publication Critical patent/CS414591A3/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5428IL-10
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CS914145A 1989-06-28 1991-12-30 Cytokinin synthesis inhibition factor, antagonists thereof and its use CS414591A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37266789A 1989-06-28 1989-06-28
US45395189A 1989-12-20 1989-12-20

Publications (1)

Publication Number Publication Date
CS414591A3 true CS414591A3 (en) 1992-12-16

Family

ID=27005854

Family Applications (1)

Application Number Title Priority Date Filing Date
CS914145A CS414591A3 (en) 1989-06-28 1991-12-30 Cytokinin synthesis inhibition factor, antagonists thereof and its use

Country Status (22)

Country Link
EP (2) EP0567450B1 (no)
JP (1) JP2813063B2 (no)
KR (1) KR0183035B1 (no)
CN (3) CN1318589C (no)
AT (1) ATE180833T1 (no)
AU (1) AU635058B2 (no)
CA (1) CA2062763C (no)
CS (1) CS414591A3 (no)
DE (1) DE69033143T2 (no)
DK (1) DK0567450T3 (no)
ES (1) ES2132068T3 (no)
FI (1) FI107926B (no)
GR (1) GR3030404T3 (no)
HK (2) HK1040493B (no)
HU (1) HU216310B (no)
IL (1) IL94878A (no)
NO (1) NO301718B1 (no)
NZ (1) NZ234291A (no)
PT (1) PT94514B (no)
SG (1) SG52282A1 (no)
TW (1) TW218383B (no)
WO (1) WO1991000349A1 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
ATE116550T1 (de) * 1991-01-16 1995-01-15 Schering Corp Behandlung von neoplastischen krankenheiten mit interleukin-10.
EP0567586B1 (en) * 1991-01-16 1995-07-12 Schering Corporation Use of interleukin-10 in adoptive immunotherapy of cancer
US6106823A (en) * 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
DK0600970T3 (da) * 1991-08-06 2000-05-29 Schering Corp Anvendelse af interleukin-10-analoger eller -antagonister til behandling af endotoksin- eller superantigeninduceret tokscit
US6277635B1 (en) 1992-03-04 2001-08-21 Schering Corporation Use of interleukin-10 to produce a population of suppressor cells
US6884410B1 (en) 1992-03-04 2005-04-26 Schering Corporation Methods for modulating antigen-specific immune responses
JPH07504437A (ja) * 1992-03-04 1995-05-18 シェリング・コーポレーション 対宿主性移植片病を抑制するインターロイキン−10の使用
WO1993018783A1 (en) * 1992-03-20 1993-09-30 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
HU220103B (hu) * 1992-08-20 2001-10-28 Schering-Plough Corp. IL-10 új alkalmazása
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
AU4856793A (en) * 1992-09-18 1994-04-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Restoration of immunocompetency to t helper cells in hiv infected patients
CA2145863A1 (en) * 1992-10-01 1994-04-28 Martha W. Bond Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
AU6000894A (en) * 1993-02-01 1994-08-29 Michel Goldman Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
NZ269663A (en) * 1993-07-26 1997-09-22 Schering Corp Agonists and antagonists of il-10
US5650060A (en) * 1994-01-28 1997-07-22 Minnesota Mining And Manufacturing Company Ionically conductive agent, system for cathodic protection of galvanically active metals, and method and apparatus for using same
EE03451B1 (et) 1994-07-05 2001-06-15 Steeno Research Group A/S Immunomodulaatorid
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
CN100389126C (zh) * 1995-12-13 2008-05-21 儿童医学中心公司 内皮细胞增殖抑制剂及其应用方法
WO1997026278A1 (en) * 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
KR20000005539A (ko) * 1996-04-17 2000-01-25 패트릭 티. 프렌더가스트 Dhea복합요법
CA2264918A1 (en) * 1996-09-06 1998-03-12 Schering Corporation Method for lowering cholesterol levels
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US6465176B1 (en) * 1998-10-02 2002-10-15 Message Pharmaceuticals, Inc. Method for identifying compounds RNA/RNA binding protein interactions
AU5047600A (en) * 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
KR20020091170A (ko) 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 B 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-cd20의 조합된 사용
EP2582386A2 (en) 2010-06-16 2013-04-24 Allergan, Inc. Il-10 and methods of treating ocular and other diseases
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3054156A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
GB202003428D0 (en) * 2020-03-10 2020-04-22 Univ Dundee IL-10 mutiens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
IE62650B1 (en) * 1989-08-04 1995-02-22 David & Sons Ltd Dispensing apparatus
PH31669A (en) * 1989-12-20 1999-01-18 Schering Corp Bcrf1 proteins as inhibitors of interferon-gamma.

Also Published As

Publication number Publication date
HUT61048A (en) 1992-11-30
IL94878A (en) 2003-01-12
EP0567450A1 (en) 1993-11-03
SG52282A1 (en) 1998-09-28
CN1317569A (zh) 2001-10-17
ATE180833T1 (de) 1999-06-15
HK1008834A1 (en) 1999-05-21
PT94514A (pt) 1991-04-18
CN1318589C (zh) 2007-05-30
HK1040493A1 (en) 2002-06-14
CN1317343A (zh) 2001-10-17
DE69033143T2 (de) 1999-10-21
WO1991000349A1 (en) 1991-01-10
HU216310B (hu) 1999-06-28
HK1040531A1 (en) 2002-06-14
KR0183035B1 (ko) 1999-04-01
CN1198642C (zh) 2005-04-27
AU6077090A (en) 1991-01-17
NO915115L (no) 1992-02-26
EP0405980A1 (en) 1991-01-02
EP0567450B1 (en) 1999-06-02
GR3030404T3 (en) 1999-09-30
CN1051393A (zh) 1991-05-15
NO301718B1 (no) 1997-12-01
CA2062763A1 (en) 1990-12-29
NZ234291A (en) 1992-11-25
HU906705D0 (en) 1992-03-30
PT94514B (pt) 1998-02-27
HK1040493B (zh) 2005-12-16
NO915115D0 (no) 1991-12-27
FI916126A0 (fi) 1991-12-27
TW218383B (no) 1994-01-01
KR920701437A (ko) 1992-08-11
ES2132068T3 (es) 1999-08-16
DK0567450T3 (da) 1999-12-13
CA2062763C (en) 2010-01-05
DE69033143D1 (de) 1999-07-08
IL94878A0 (en) 1991-04-15
HK1040531B (zh) 2008-01-11
FI107926B (fi) 2001-10-31
AU635058B2 (en) 1993-03-11
JPH04502560A (ja) 1992-05-14
JP2813063B2 (ja) 1998-10-22

Similar Documents

Publication Publication Date Title
CS414591A3 (en) Cytokinin synthesis inhibition factor, antagonists thereof and its use
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
ES2156852T3 (es) Citoquina mamifera, il-11.
DK20690D0 (da) Alkoxy-1,2,4-triazolo(1,5-c)pyrimidin-2-sulfonamider, fremgangsmaade til deres fremstilling og mellemprodukter
CA2193993A1 (en) New hil-4 mutant proteins used as antagonists or partial agonists of human interleukin 4
IL94602A0 (en) Polypeptides and polypeptide analogues
CA2123315A1 (en) Therapeutic agents which are antagonists or partial agonists of human interleukin 4
RU94044322A (ru) Замещенные в кольце z-амино-1,2,3,4-тетрагидронафталины и 3-аминохроманы
NO922456L (no) Bcrf1-proteiner som inhibitorer av interferon-gamma
EP0553294A4 (en) Methods and compositions for the treatment of cell proliferation disorders
ATE111357T1 (de) Synergetische immunostimulierende zusammensetzung und ihre verwendung.
IT8721560A0 (it) Procedimento per la purificazione di interferone.
IT8504867A0 (it) Dispositivo di fissaggio per piastre frontali regolabili di parti di mobile estraibili.
ES8802309A1 (es) Procedimiento para la obtencion de piridiletil-dihidropiridinas
CA2080355A1 (en) Isolated Viral Protein Cytokine Antagonists
ITMI931034A1 (it) Processo per la preparazione di proteine inibenti i ribosomi
IT8945801A0 (it) Procedimento per la fabbricazione di pannelli sagomati per mobili

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic